Virtual Library

Start Your Search

Samuel Bernal



Author of

  • +

    P2.04 - Immuno-oncology (ID 167)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Immuno-oncology
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.04-56 - Improved Survival of NSCLC Filipino Patients Given Autologous Dendritic Cell Vaccine: Case Series with CTC Upgrade and IL15 (Now Available) (ID 2938)

      10:15 - 18:15  |  Author(s): Samuel Bernal

      • Abstract
      • Slides

      Background

      Lung cancer remains to be a major malignancy among Filipinos with a fatality rate of 19.2 for every 100,000 in 2018. The Molecular Diagnostics and Cellular Therapeutics Laboratory of the Lung Center of the Philippines has developed a complimentary therapy using autologous dendritic cell vaccine for lung adenocarcinoma, the preliminary result of which was reported in this Conference in 2013. From then onwards, a number of modifications has been incorporated in the protocol as part of the continuing research and development program of the Center. Herein, reported is the comparative performance of the vaccination protocol in the period 2009-2013 and 2014-2018 and the modifications introduced that accounted for the improved survival.

      Method

      Chart data of sixteen lung adenocarcinoma patients in 2009-2013 and five patients in 2014-2018 who have undergone the immune cell therapy as part of their treatment regimen, were retrieved and compared in terms of their survival in 3, 6 and 9 month timepoints. Protocol for immune cell therapy in the same period were also retrieved and compared. The patients have executed corresponding informed consent and their therapy has undergone ethics review and approval of the Stem Cell Ethics Committee of the Center.

      Result

      Patients in 2009-2013 included 1 stage1, 1 stage 2, 6 stage 3 and 8 stage 4, while patients in 2014-2018 included 1 stage 1 and 4 stage 4. For stage 1, there was a 100% survival in the 3, 6 and 9 month timepoints in both periods. For stage 4 there was a 87.5%, 50% and 12.5% survival respectively in the 3, 6 and 9 month timepoints for the 2009-2013 period while a 100%, 75% and75% survival for 2014-2018 period.

      Protocol evaluation showed an increase in circulating tumor gene targets used for peptide priming (i.e. from 15 to 22 targets) and the use of IL15. The additional targets included were: BRACHURY, CD133, hTERT, p53, NRAS, S100A14, and CA125

      Conclusion

      Although preliminary, the additional targets and the use of IL15 could be attributed to the improved survival rate of patients, especially for stage 4 patients.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.